Drug
Rotigotine clinical trials
Also written Neupro and SPM 962.
- studies test it
- 77
- open now
- 2
- in phase 3
- 33
- first study started
- 1999
Keep track of what changes. Save the rotigotine studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
77 studies that test it; most in 2012 (13)
| Year | Studies |
|---|---|
| 1999 | 1 |
| 2002 | 5 |
| 2003 | 1 |
| 2004 | 5 |
| 2005 | 6 |
| 2006 | 7 |
| 2007 | 7 |
| 2008 | 4 |
| 2009 | 3 |
| 2010 | 3 |
| 2011 | 5 |
| 2012 | 13 |
| 2013 | 3 |
| 2014 | 2 |
| 2016 | 4 |
| 2018 | 1 |
| 2019 | 2 |
| 2021 | 2 |
| 2023 | 2 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 14
- Phase 2
- 20
- Phase 3
- 33
- Phase 4
- 11
- No phase
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 64 · Other 13
UCB Pharma (36) · Otsuka Pharmaceutical Co., Ltd. (10) · UCB BIOSCIENCES GmbH (9) · I.R.C.C.S. Fondazione Santa Lucia (3) · UCB BIOSCIENCES, Inc. (2) · UCB Biopharma SRL (2) · Virginia Commonwealth University (1) · SocraTec R&D GmbH (1)
Studies
Open first, then newest update. How each study uses rotigotine is read from its arms, and is right about nine times in ten.
Testing it · 77
- Adhesion and Safety of Rotigexole Compared to Neupro®Not yet recruitingNot applicableEva PharmaNCT07015346Written as Rotigexole 8 mg
- A Phase 3 Study of Rotigotine in Combination with Rivastigmine in Mild to Moderate Alzheimer's DiseaseRecruitingPhase 3I.R.C.C.S. Fondazione Santa LuciaNCT06702124Written as Rotigotine 4Mg/24Hrs Patch
- Transdermal Rotigotine as Adjunct to Behavioral Therapy for Cocaine Use DisorderCompletedPhase 2Virginia Commonwealth UniversityNCT05886582Written as Rotigotine Transdermal System [Neupro]
- Dopaminergic Therapy for Frontotemporal Dementia PatientsCompletedPhase 2I.R.C.C.S. Fondazione Santa LuciaNCT04937452Written as Rotigotine 4Mg/24Hrs Patch
- Clinical Trial to Investigate Patch Adhesion of Rotigotine Containing Patches in Patients With Parkinson's DiseaseCompletedPhase 2SocraTec R&D GmbHNCT06247410Written as Rotigotine 8Mg/24Hrs Patch
- A Follow-up Study of Rotigotine Patch in Adolescent Subjects With Restless Legs SyndromeTerminatedPhase 3UCB Biopharma SRLNCT03992196Written as Rotigotine 1 mg/24 h
- A Study of Rotigotine Patch in Adolescent Subjects With Restless Legs Syndrome of Unknown CauseTerminatedPhase 3UCB Biopharma SRLNCT03728933Written as Rotigotine 1 milligram/24 hours
- An Open, Randomised, Single Dose, 2-period, 2-sequence Crossover Adhesion Study of Two Different Transdermal Patches Containing Rotigotine.TerminatedPhase 1SandozNCT04183634Written as Neupro (Reference)
- Anxiety in Parkinson's: Use of Quantitative Methods to Guide Rational TreatmentTerminatedPhase 4Johns Hopkins UniversityNCT02365870Written as rotigotine transdermal patch
- Effects of Dopaminergic Therapy in Patients With Alzheimer's DiseaseCompletedPhase 2I.R.C.C.S. Fondazione Santa LuciaNCT03250741Written as Rotigotine transdermal patch
- Trial to Evaluate The Efficacy Of Rotigotine on Parkinson's Disease-Associated Motor Symptoms And ApathyCompletedPhase 4UCB BIOSCIENCES GmbHNCT01782222Written as Rotigotine
- Effect of Rotigotine Patch Treatment on Cardiovascular Markers in Idiopathic Restless Legs SyndromeCompletedPhase 4University Hospital, MontpellierNCT01823770Written as Rotigotine
- Rotigotine Versus Placebo, A Study To Evaluate The Efficacy In Advanced Stage Idiopathic Parkinson's Disease PatientsCompletedPhase 3UCB PharmaNCT01646255Written as Rotigotine
- Dose Escalating Study of Rotigotine in Pediatric Subjects With Restless Legs SyndromeCompletedPhase 2UCB BIOSCIENCES, Inc.NCT01495793Written as Rotigotine
- Non Motors Aspects in De Novo Parkinson's DiseaseStatus unknownPhase 3University Hospital, GrenobleNCT02786667Written as Rotigotine
- Long-Term Follow-Up Study for Safety, Efficacy and Tolerability of Rotigotine in Adolescents With Restless Legs SyndromeCompletedPhase 2UCB BIOSCIENCES, Inc.NCT01498120Written as Rotigotine
- Rotigotine Effect on Nocturnal Hypokinesia Compares to Placebo Control: A Quantitative Assessment by Wearable SensorsStatus unknownPhase 4Chulalongkorn UniversityNCT03098368Written as Rotigotine
- Pharmacokinetic Profile of Neupro Patch Administrated at 2 mg, 4 mg, 6 mg and 8 mg/Day Weekly in Patients With Early-stage Parkinson's DiseaseCompletedPhase 1Luye Pharma Group Ltd.NCT02728947Written as ROTIGOTINE
- Switching From Oral Dopamine Agonists to RotigotineCompletedPhase 4John Winkelman, MD, PhDNCT01976871Written as Rotigotine
- Irritation and Sensitization Potential of Repeat Applications of Rotigotine PatchCompletedPhase 1Inflamax Research IncorporatedNCT02727205Written as Rotigotine Transdermal System
See all 77 studies that test rotigotine →
Given in every arm · 1 — rotigotine is usual care beside what is tested
As the comparator · 2 — what is tested is compared with rotigotine
- A Study to Assess Pharmacokinetic Profiles of LY03003 and NeuproCompletedPhase 1Luye Pharma Group Ltd.NCT03733561Written as Neupro 4Mg/24Hr Transdermal Patch
- Pharmacokinetics and Safety Study of LY03003 in Patients With Early-stage Parkinson's DiseaseCompletedPhase 1Luye Pharma Group Ltd.NCT02055274Written as Neupro
Codes
What other systems call rotigotine · ClinicalTrials.gg INT003250
- MeSH (NLM) C047508rotigotineConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 87T4T8BO2EROTIGOTINEConfirmed FDA, NLM, Wikidata
- UNII (FDA) 5QTR54Z0E1ROTIGOTINE, (+/-)-Confirmed NLM, Wikidata
- UNII (FDA) N8FO6Z42IRROTIGOTINE, (+)-Confirmed NLM, Wikidata
- RxNorm 616739Confirmed FDA, Wikidata
- Wikidata Q411985(6S)-rotigotineConfirmed FDA, NLM, Wikidata
- Wikidata Q27262758(+/-)-rotigotineConfirmed NLM, Wikidata
- Wikidata Q27284704(+)-rotigotineConfirmed NLM, Wikidata
- NCI Thesaurus C77566RotigotineOne source FDA
- DrugBank DB05271One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C047508 | rotigotine | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 87T4T8BO2E | ROTIGOTINE | Confirmed FDA, NLM, Wikidata |
| UNII (FDA) | 5QTR54Z0E1 | ROTIGOTINE, (+/-)- | Confirmed NLM, Wikidata |
| UNII (FDA) | N8FO6Z42IR | ROTIGOTINE, (+)- | Confirmed NLM, Wikidata |
| RxNorm | 616739 | — | Confirmed FDA, Wikidata |
| Wikidata | Q411985 | (6S)-rotigotine | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27262758 | (+/-)-rotigotine | Confirmed NLM, Wikidata |
| Wikidata | Q27284704 | (+)-rotigotine | Confirmed NLM, Wikidata |
| NCI Thesaurus | C77566 | Rotigotine | One source FDA |
| DrugBank | DB05271 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.